US5153312A
(en)
*
|
1990-09-28 |
1992-10-06 |
American Cyanamid Company |
Oligosaccharide conjugate vaccines
|
US7279162B1
(en)
|
1990-10-22 |
2007-10-09 |
Henry M. Jackson Foundation For The Advancement Of Military Medicine |
Isolated broadly reactive opsonic immunoglobulin for treating a pathogenic coagulase-negative staphylococcus infection
|
US5622649A
(en)
*
|
1991-06-27 |
1997-04-22 |
Emory University |
Multiple emulsions and methods of preparation
|
FR2682388B1
(fr)
*
|
1991-10-10 |
1995-06-09 |
Pasteur Merieux Serums Vacc |
Procede de preparation d'un oligoside par depolymerisation d'un polyoside issu d'un agent pathogene, oligoside ainsi obtenu et son utilisation notamment comme agent vaccinal.
|
CA2129899C
(fr)
*
|
1992-02-11 |
2011-01-04 |
James J. Mond |
Modele immunogenique a double porteur
|
US7141244B1
(en)
*
|
1992-03-02 |
2006-11-28 |
Chiron Srl |
Helicobacter pylori proteins useful for vaccines and diagnostics
|
US5445817A
(en)
*
|
1992-08-21 |
1995-08-29 |
The United States Of America As Represented By The Department Of Health And Human Services |
Pertussis toxin used as a carrier protein with non-charged saccharides in conjugate vaccines
|
ATE211654T1
(de)
*
|
1992-09-16 |
2002-01-15 |
Univ Tennessee Res Corp |
Antigene des hybriden m-proteins und träger für gruppe a streptokokkenimpfstoff
|
US6531156B1
(en)
|
1994-04-15 |
2003-03-11 |
Temple University |
Aqueous solven encapsulation method, apparatus and microcapsules
|
JPH10502366A
(ja)
*
|
1994-07-01 |
1998-03-03 |
リカン・リミテッド |
ヘリコバクター・ピロリ抗原タンパク質調製品およびイムノアッセイ
|
US5565204A
(en)
*
|
1994-08-24 |
1996-10-15 |
American Cyanamid Company |
Pneumococcal polysaccharide-recombinant pneumolysin conjugate vaccines for immunization against pneumococcal infections
|
US5695768A
(en)
*
|
1995-06-07 |
1997-12-09 |
Alberta Research Council |
Immunostimulating activity of Streptococcus pneumoniae serotype 8 oligosaccharides
|
US5866132A
(en)
*
|
1995-06-07 |
1999-02-02 |
Alberta Research Council |
Immunogenic oligosaccharide compositions
|
IL121585A0
(en)
*
|
1995-06-07 |
1998-02-08 |
Alberta Res Council |
Immunogenic and immunostimulatory oligosaccharide compositions and methods of preparing and using them
|
US6284884B1
(en)
|
1995-06-07 |
2001-09-04 |
North American Vaccine, Inc. |
Antigenic group B streptococcus type II and type III polysaccharide fragments having a 2,5-anhydro-D-mannose terminal structure and conjugate vaccine thereof
|
PL184872B1
(pl)
|
1995-06-23 |
2003-01-31 |
Smithkline Beecham Biolog |
Kombinowana szczepionkaĆ zestaw do przygotowania kombinowanej szczepionkiĆ sposób wytwarzania kombinowanej szczepionki i jej zastosowanie
|
US6872398B2
(en)
*
|
1995-12-22 |
2005-03-29 |
The United States Of America As Represented By The Secretary Of The Army |
Conjugate vaccine against gram-negative bacterial infections
|
AU1463097A
(en)
|
1996-01-04 |
1997-08-01 |
Rican Limited |
Helicobacter pylori bacterioferritin
|
ZA97248B
(en)
*
|
1996-01-18 |
1997-07-18 |
Rohm & Haas |
Method for identifying and quantifying polymers utilizing immunoassay techniques
|
US6207157B1
(en)
|
1996-04-23 |
2001-03-27 |
The United States Of America As Represented By The Department Of Health And Human Services |
Conjugate vaccine for nontypeable Haemophilus influenzae
|
US6309646B1
(en)
|
1996-05-09 |
2001-10-30 |
The Henry M. Jackson Foundation For The Advancement Of Military Medicine |
Protein-polysaccharide conjugate vaccines and other immunological reagents prepared using homobifunctional and heterobifunctional vinylsulfones, and processes for preparing the conjugates
|
CA2264735C
(fr)
*
|
1996-08-27 |
2008-01-29 |
Chiron Corporation |
Glycoconjugues du groupe serologique b de neisseria meningitidis et leurs procedes d'utilisation
|
US6299881B1
(en)
*
|
1997-03-24 |
2001-10-09 |
Henry M. Jackson Foundation For The Advancement Of Military Medicine |
Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts
|
US6610293B1
(en)
|
1997-06-16 |
2003-08-26 |
The Henry M. Jackson Foundation For The Advancement Of Military Medicine |
Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria
|
US5847110A
(en)
*
|
1997-08-15 |
1998-12-08 |
Biomedical Frontiers, Inc. |
Method of reducing a schiff base
|
NZ503488A
(en)
|
1997-10-03 |
2001-08-31 |
Galencia Pharmaceuticals Inc |
Polysaccharide conjugate derivatives capable of binding to the cell surface of antigen processing cells (APCs) and acting as immunoadjuvants
|
ATE421339T1
(de)
|
1998-02-05 |
2009-02-15 |
Jackson H M Found Military Med |
Vereinfachte methode zur entfernung von freiem protein während der herstellung von protein- polysaccharid-konjugaten und impfstoffen unter verwendung von medien mit limitierter durchlässigkeit
|
CN1200730C
(zh)
*
|
1998-02-12 |
2005-05-11 |
惠氏控股有限公司 |
用白细胞介素-12配制的肺炎球菌和脑膜炎球菌疫苗
|
US7018637B2
(en)
*
|
1998-02-23 |
2006-03-28 |
Aventis Pasteur, Inc |
Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines
|
US6573245B1
(en)
|
1998-04-28 |
2003-06-03 |
Galenica Pharmaceuticals, Inc. |
Modified polysaccharide adjuvant-protein antigen conjugates, the preparation thereof and the use thereof
|
US7250494B2
(en)
*
|
1998-06-15 |
2007-07-31 |
Biosynexus Incorporated |
Opsonic monoclonal and chimeric antibodies specific for lipoteichoic acid of Gram positive bacteria
|
US6858211B1
(en)
|
1998-07-20 |
2005-02-22 |
The United States Of America As Represented By The Department Of Health And Human Services |
Vaccines against Escherichia coli O157 infection
|
AU771330B2
(en)
*
|
1998-08-19 |
2004-03-18 |
Baxter Healthcare Sa |
Immunogenic beta-propionamido-linked polysaccharide protein conjugate useful as a vaccine produced using an N-acryloylated polysaccharide
|
US6797275B1
(en)
*
|
1998-12-04 |
2004-09-28 |
The United States Of America As Represented By The Department Of Health And Human Services |
Method of immunizing humans against Salmonella typhi using a Vi-rEPA conjugate vaccine
|
US6146902A
(en)
*
|
1998-12-29 |
2000-11-14 |
Aventis Pasteur, Inc. |
Purification of polysaccharide-protein conjugate vaccines by ultrafiltration with ammonium sulfate solutions
|
GB9928196D0
(en)
*
|
1999-11-29 |
2000-01-26 |
Chiron Spa |
Combinations of B, C and other antigens
|
FR2806304B1
(fr)
*
|
2000-03-17 |
2002-05-10 |
Aventis Pasteur |
Conjugues polysaccharidiques du pneumocoque a usage vaccinal contre le tetanos et la diphterie
|
JP2004515450A
(ja)
*
|
2000-04-18 |
2004-05-27 |
エンドバイオロジックス, インコーポレイテッド |
敗血症処置のためのリポ多糖結合体ワクチン
|
US7749511B2
(en)
*
|
2000-04-18 |
2010-07-06 |
Endobiologics, Incorporated |
Anti-sepsis conjugate vaccine
|
ATE357461T1
(de)
*
|
2000-08-25 |
2007-04-15 |
Aventis Pasteur |
Innen-kern oligosaccharide epitopes aus lipopolysacchariden von haemophilus influenza als vakzinen in der prophylaktischen behandlung von haemophilus influenzae infektionen
|
US7723296B2
(en)
*
|
2001-01-18 |
2010-05-25 |
Genzyme Corporation |
Methods for introducing mannose-6-phosphate and other oligosaccharides onto glycoproteins and its application thereof
|
MXPA03006561A
(es)
|
2001-01-23 |
2004-10-15 |
Aventis Pasteur |
Vacuna del conjugado proteina-polisacarido meningococico, multivalente.
|
GB0115176D0
(en)
|
2001-06-20 |
2001-08-15 |
Chiron Spa |
Capular polysaccharide solubilisation and combination vaccines
|
GB0118249D0
(en)
|
2001-07-26 |
2001-09-19 |
Chiron Spa |
Histidine vaccines
|
GB0121591D0
(en)
|
2001-09-06 |
2001-10-24 |
Chiron Spa |
Hybrid and tandem expression of neisserial proteins
|
JP2005506322A
(ja)
*
|
2001-08-31 |
2005-03-03 |
カイロン ソチエタ ア レスポンサビリタ リミタータ |
Helicobacterpyloriワクチン接種
|
GB0129007D0
(en)
*
|
2001-12-04 |
2002-01-23 |
Chiron Spa |
Adjuvanted antigenic meningococcal compositions
|
EP2572707A3
(fr)
*
|
2002-02-20 |
2013-11-06 |
Novartis Vaccines and Diagnostics, Inc. |
Microparticules avec des molécules contenant un polypeptide adsorbé
|
EP1476197B1
(fr)
*
|
2002-02-22 |
2009-01-07 |
National Research Council Of Canada |
Synthese de vaccins conjugues de proteine-lipopolysaccharide au moyen de la region lipidique apres retrait du residu de phosphate glycosidique
|
WO2003094961A1
(fr)
*
|
2002-05-09 |
2003-11-20 |
Massimo Porro |
Vaccins de polysaccharides et de glycoconjugues ameliores
|
MXPA04011249A
(es)
|
2002-05-14 |
2005-06-06 |
Chiron Srl |
Vacunas mucosales con adyuvante de quitosano y antigenos meningococicos.
|
GB0211118D0
(en)
|
2002-05-15 |
2002-06-26 |
Polonelli Luciano |
Vaccines
|
SI2255826T1
(sl)
|
2002-08-02 |
2016-07-29 |
Glaxosmithkline Biologicals S.A. |
Neisserijski vakcinski sestavki, ki obsegajo kombinacijo antigenov
|
SI1549338T1
(sl)
|
2002-10-11 |
2011-04-29 |
Novartis Vaccines & Diagnostic |
Polipeptidna cepiva za ĺ iroko zaĺ äśito pred hipervirulentnimi miningokoknimi rodovi
|
ES2649048T3
(es)
|
2002-11-01 |
2018-01-09 |
Glaxosmithkline Biologicals S.A. |
Procedimiento de secado
|
GB0227346D0
(en)
|
2002-11-22 |
2002-12-31 |
Chiron Spa |
741
|
US8034378B2
(en)
|
2002-12-27 |
2011-10-11 |
Novartis Vaccines And Diagnostics, Inc |
Immunogenic compositions containing phospholipid
|
FR2850106B1
(fr)
*
|
2003-01-17 |
2005-02-25 |
Aventis Pasteur |
Conjugues obtenus par amination reductrice du polysaccharide capsulaire du pneumocoque de serotype 5
|
ES2411080T3
(es)
|
2003-01-30 |
2013-07-04 |
Novartis Ag |
Vacunas inyectables contra múltiples serogrupos de meningococos
|
US7893096B2
(en)
|
2003-03-28 |
2011-02-22 |
Novartis Vaccines And Diagnostics, Inc. |
Use of small molecule compounds for immunopotentiation
|
JP2007516219A
(ja)
|
2003-05-07 |
2007-06-21 |
アヴェンティス パストゥール インコーポレイテッド |
髄膜炎菌ワクチン接種に対する免疫原性の増強の方法
|
EP2386313A1
(fr)
|
2003-05-07 |
2011-11-16 |
Sanofi Pasteur, Inc. |
Conjugués de polysaccharides-protéines dérivatisés méningococciques multivalents et vaccin
|
JP5557415B2
(ja)
|
2003-06-02 |
2014-07-23 |
ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド |
吸着させたトキソイドおよび多糖類含有抗原を含む微粒子に基づく免疫原性組成物
|
GB0313916D0
(en)
|
2003-06-16 |
2003-07-23 |
Glaxosmithkline Biolog Sa |
Vaccine composition
|
MXPA05014015A
(es)
*
|
2003-06-23 |
2006-03-17 |
Baxter Int |
Vacunas contra grupo y nisseria meningitidis y combinaciones meningococales del mismo.
|
MXPA05014171A
(es)
|
2003-06-23 |
2007-02-21 |
Sanofi Pasteur Inc |
Metodo de inmunizacion contra neisseria meningitidis serogrupos a y c.
|
GB0323103D0
(en)
|
2003-10-02 |
2003-11-05 |
Chiron Srl |
De-acetylated saccharides
|
PL1961426T3
(pl)
|
2003-10-02 |
2012-03-30 |
Gsk Vaccines S R L |
Skojarzone szczepionki przeciwko zapaleniu opon mózgowo-rdzeniowych
|
DE602004028262D1
(de)
|
2003-10-02 |
2010-09-02 |
Glaxosmithkline Biolog Sa |
B. pertussis antigene und ihre verwendung bei der vakzinierung
|
SG149013A1
(en)
|
2003-12-17 |
2009-01-29 |
Wyeth Corp |
Immunogenic peptide carrier conjugates and methods of producing same
|
JP4696079B2
(ja)
|
2003-12-17 |
2011-06-08 |
ヤンセン アルツハイマー イミュノセラピー |
Aβ免疫原性ペプチド担体結合物およびそれの製造方法
|
US7422755B2
(en)
*
|
2004-01-15 |
2008-09-09 |
The United States Of America As Represented By The Department Of Health And Human Services |
Antimultiorganism glycoconjugate vaccine
|
EP1713508A2
(fr)
*
|
2004-01-29 |
2006-10-25 |
Biosynexus Incorporated |
Utilisation de groupes fonctionnels amino-oxy dans la preparation de vaccins
|
GB0406013D0
(en)
|
2004-03-17 |
2004-04-21 |
Chiron Srl |
Analysis of saccharide vaccines without interference
|
GB0408978D0
(en)
|
2004-04-22 |
2004-05-26 |
Chiron Srl |
Meningococcal fermentation for preparing conjugate vaccines
|
GB0409745D0
(en)
|
2004-04-30 |
2004-06-09 |
Chiron Srl |
Compositions including unconjugated carrier proteins
|
GB0500787D0
(en)
|
2005-01-14 |
2005-02-23 |
Chiron Srl |
Integration of meningococcal conjugate vaccination
|
SI1740217T1
(sl)
|
2004-04-30 |
2011-10-28 |
Novartis Ag |
Konjugirano meningokokno cepljenje
|
GB0411387D0
(en)
|
2004-05-21 |
2004-06-23 |
Chiron Srl |
Analysis of saccharide length
|
GB0413868D0
(en)
|
2004-06-21 |
2004-07-21 |
Chiron Srl |
Dimensional anlaysis of saccharide conjugates
|
EP2277595A3
(fr)
|
2004-06-24 |
2011-09-28 |
Novartis Vaccines and Diagnostics, Inc. |
Composés pour potentialiser l'immunité
|
WO2006115509A2
(fr)
|
2004-06-24 |
2006-11-02 |
Novartis Vaccines And Diagnostics Inc. |
Immuno-potentialisateurs a petites molecules et analyses visant a detecter leur presence
|
US20060165716A1
(en)
|
2004-07-29 |
2006-07-27 |
Telford John L |
Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae
|
WO2006026689A2
(fr)
|
2004-08-30 |
2006-03-09 |
Sanofi Pasteur, Inc. |
Conjugues polysaccharide/proteine derivatises de meningocoque multivalents et vaccin
|
GB0420466D0
(en)
*
|
2004-09-14 |
2004-10-20 |
Cassone Antonio |
Anti-glucan antibodies
|
WO2006034320A2
(fr)
|
2004-09-21 |
2006-03-30 |
Sanofi Pasteur, Inc. |
Conjugues polysaccharide/proteine menogococciques multivalents derivatises et vaccin
|
GB0502095D0
(en)
|
2005-02-01 |
2005-03-09 |
Chiron Srl |
Conjugation of streptococcal capsular saccharides
|
GB0502096D0
(en)
|
2005-02-01 |
2005-03-09 |
Chiron Srl |
Purification of streptococcal capsular polysaccharide
|
GB0505518D0
(en)
|
2005-03-17 |
2005-04-27 |
Chiron Srl |
Combination vaccines with whole cell pertussis antigen
|
GB0505996D0
(en)
|
2005-03-23 |
2005-04-27 |
Glaxosmithkline Biolog Sa |
Fermentation process
|
US20070184072A1
(en)
|
2005-04-08 |
2007-08-09 |
Wyeth |
Multivalent pneumococcal polysaccharide-protein conjugate composition
|
US7709001B2
(en)
|
2005-04-08 |
2010-05-04 |
Wyeth Llc |
Multivalent pneumococcal polysaccharide-protein conjugate composition
|
US7955605B2
(en)
*
|
2005-04-08 |
2011-06-07 |
Wyeth Llc |
Multivalent pneumococcal polysaccharide-protein conjugate composition
|
AU2011253684B8
(en)
*
|
2005-04-08 |
2013-07-11 |
Wyeth Llc |
Multivalent pneumococcal polysaccharide-protein conjugate composition
|
CA2604363C
(fr)
|
2005-04-08 |
2015-06-16 |
Wyeth |
Composition conjuguee polysaccharide-proteine pneumococcique polyvalente
|
NZ564606A
(en)
|
2005-06-27 |
2010-10-29 |
Glaxosmithkline Biolog Sa |
Immunogenic composition comprising atleast two N. meningitidis capsular polysaccharides conjugated through a linker protein
|
WO2007026249A2
(fr)
|
2005-09-01 |
2007-03-08 |
Novartis Vaccines And Diagnostics Gmbh & Co Kg |
Vaccination multiple comprenant des meningocoques du serogroupe c
|
JP5044754B2
(ja)
*
|
2005-09-21 |
2012-10-10 |
アメリカ合衆国 |
カンピロバクター・ジェジュニに対するワクチン成分として使用される免疫原莢膜組成物
|
US7700578B2
(en)
*
|
2005-09-21 |
2010-04-20 |
The United States Of America As Represented By The Secretary Of The Navy |
Capsule composition for use as immunogen against Campylobacter jejuni
|
US9999591B2
(en)
*
|
2005-09-21 |
2018-06-19 |
The United States Of America As Represented By The Secretary Of The Navy |
Immunogenic composition against Campylobacter jejuni
|
GB0522303D0
(en)
|
2005-11-01 |
2005-12-07 |
Chiron Srl |
Culture method
|
ES2514316T3
(es)
|
2005-11-22 |
2014-10-28 |
Novartis Vaccines And Diagnostics, Inc. |
Partículas similares a virus (VLPs) de Norovirus y Sapovirus
|
GB0524066D0
(en)
|
2005-11-25 |
2006-01-04 |
Chiron Srl |
741 ii
|
GB0607088D0
(en)
|
2006-04-07 |
2006-05-17 |
Glaxosmithkline Biolog Sa |
Vaccine
|
NO346529B1
(no)
|
2005-12-22 |
2022-09-26 |
Glaxosmithkline Biologicals Sa |
Bruk av et immunogenpreparat for småbarn, omfattende 22F sakkaridkonjugat
|
JP4822854B2
(ja)
*
|
2006-01-18 |
2011-11-24 |
株式会社有沢製作所 |
フレキシブルプリント配線板用ポリアミドイミド樹脂、並びに該樹脂を用いた金属張り積層板、カバーレイ、フレキシブルプリント配線板、及び樹脂組成物
|
PL2004225T3
(pl)
|
2006-03-22 |
2012-09-28 |
Novartis Ag |
Schematy immunizacji koniugatami meningokokowymi
|
GB0605757D0
(en)
|
2006-03-22 |
2006-05-03 |
Chiron Srl |
Separation of conjugated and unconjugated components
|
EP2007765B1
(fr)
|
2006-03-23 |
2012-06-27 |
Novartis AG |
Composes de potentialisation immunitaire
|
ATE539079T1
(de)
|
2006-03-23 |
2012-01-15 |
Novartis Ag |
Imidazochinoxalinverbindungen als immunmodulatoren
|
CA2647100A1
(fr)
*
|
2006-03-23 |
2007-09-27 |
Novartis Ag |
Procedes de preparation de composes contenant de l'imidazole
|
US8808707B1
(en)
|
2006-05-08 |
2014-08-19 |
Wyeth Llc |
Pneumococcal dosing regimen
|
EP2035035A2
(fr)
|
2006-06-09 |
2009-03-18 |
Novartis AG |
Compositions immunogenes pour streptococcus agalactiae
|
ES2658851T3
(es)
|
2006-08-07 |
2018-03-12 |
President And Fellows Of Harvard College |
Vacunas de matriz de proteína y métodos de preparación y administración de tales vacunas
|
CN101553246B
(zh)
*
|
2006-08-07 |
2019-05-21 |
哈佛大学校长及研究员协会 |
蛋白质基质疫苗及这种疫苗的制备和给药方法
|
AU2007293672B2
(en)
|
2006-09-07 |
2013-06-27 |
Glaxosmithkline Biologicals S.A. |
Vaccine
|
GB0700136D0
(en)
|
2007-01-04 |
2007-02-14 |
Glaxosmithkline Biolog Sa |
Process for manufacturing vaccines
|
GB0700562D0
(en)
|
2007-01-11 |
2007-02-21 |
Novartis Vaccines & Diagnostic |
Modified Saccharides
|
DK2457920T3
(en)
|
2007-01-18 |
2018-01-22 |
Genzyme Corp |
Oligosaccharides comprising an amino oxy group and conjugates thereof
|
KR20100017569A
(ko)
|
2007-05-02 |
2010-02-16 |
글락소스미스클라인 바이오로지칼즈 에스.에이. |
백신
|
JP5637848B2
(ja)
|
2007-06-04 |
2014-12-10 |
ノバルティス アーゲー |
髄膜炎ワクチンの製剤化
|
CN101883583B
(zh)
|
2007-06-26 |
2017-05-17 |
葛兰素史密丝克莱恩生物有限公司 |
含有肺炎链球菌荚膜多糖缀合物的疫苗
|
MX2010002773A
(es)
|
2007-09-12 |
2010-03-31 |
Novartis Ag |
Antigenos mutantes de gas57 y anticuerpos de gas57.
|
GB0818453D0
(en)
|
2008-10-08 |
2008-11-12 |
Novartis Ag |
Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
|
EP2537857B1
(fr)
|
2007-12-21 |
2017-01-18 |
GlaxoSmithKline Biologicals SA |
Formes mutantes de streptolysine O
|
SI2349520T1
(sl)
|
2008-10-27 |
2016-08-31 |
Glaxosmithkline Biologicals S.A. |
Postopek čiščenja za ogljikohidrat iz Streptococcus skupine A
|
GB0822633D0
(en)
|
2008-12-11 |
2009-01-21 |
Novartis Ag |
Formulation
|
EP3608330B1
(fr)
|
2008-12-16 |
2022-11-09 |
Genzyme Corporation |
Intermédiaires synthétiques utiles dans la préparation des conjugués oliogosaccharide-protéine
|
CN103897045A
(zh)
|
2009-01-12 |
2014-07-02 |
诺华股份有限公司 |
抗革兰氏阳性细菌疫苗中的Cna_B结构域
|
WO2010083477A2
(fr)
|
2009-01-16 |
2010-07-22 |
University Of Maryland, Baltimore |
Vaccin à large spectre contre les salmonelles non typhoïdiques
|
US20120135037A1
(en)
|
2009-06-01 |
2012-05-31 |
Mizel Steven B |
Flagellin fusion proteins and conjugates comprising pneumococcus antigens and methods of using the same
|
US8647621B2
(en)
|
2009-07-27 |
2014-02-11 |
Fina Biosolutions, Llc |
Method of producing protein-carbohydrate vaccines reduced in free carbohydrate
|
JP2013506651A
(ja)
|
2009-09-30 |
2013-02-28 |
ノバルティス アーゲー |
Staphylococcus.aureus5型および8型莢膜多糖の結合体
|
GB0917647D0
(en)
|
2009-10-08 |
2009-11-25 |
Glaxosmithkline Biolog Sa |
Expression system
|
PL2493498T3
(pl)
|
2009-10-30 |
2017-08-31 |
Glaxosmithkline Biologicals Sa |
Oczyszczanie sacharydów otoczkowych staphylococcus aureus typu 5 i typu 8
|
US9044517B2
(en)
|
2009-12-17 |
2015-06-02 |
Fina Biosolutions, Llc |
Activation of polysaccharides via the cyanylating agent, 1-cyano-4-pyrrolidinopyridinium tetrafluoroborate (CPPT), in the preparation of polysaccharide/protein conjugate vaccines
|
JP5781542B2
(ja)
|
2009-12-30 |
2015-09-24 |
ノバルティス アーゲー |
E.coliキャリアタンパク質に結合体化した多糖免疫原
|
GB201003924D0
(en)
|
2010-03-09 |
2010-04-21 |
Glaxosmithkline Biolog Sa |
Immunogenic composition
|
GB201003922D0
(en)
|
2010-03-09 |
2010-04-21 |
Glaxosmithkline Biolog Sa |
Conjugation process
|
JP2013521770A
(ja)
|
2010-03-10 |
2013-06-13 |
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム |
ワクチン組成物
|
JP2013522287A
(ja)
|
2010-03-18 |
2013-06-13 |
ノバルティス アーゲー |
血清群b髄膜炎菌のためのアジュバント添加ワクチン
|
EP2556151A1
(fr)
|
2010-04-07 |
2013-02-13 |
Novartis AG |
Procédé de génération de pseudo-particules virales de parvovirus b19
|
ES2743156T3
(es)
|
2010-04-23 |
2020-02-18 |
Serum Institute Of India Pvt Ltd |
Método simple para eliminación simultánea de múltiples impurezas a partir de sobrenadantes de cultivo a niveles ultrabajos
|
US20130116423A1
(en)
|
2010-04-23 |
2013-05-09 |
A. Stewart Campbell |
Synthetic Oligosaccharides for Staphylococcus Vaccine
|
WO2011137181A1
(fr)
|
2010-04-27 |
2011-11-03 |
Ancora Pharmaceuticals Inc. |
Oligosaccharides synthétiques pour vaccins contre moraxella
|
WO2011149778A1
(fr)
|
2010-05-26 |
2011-12-01 |
Ancora Pharmaceuticals Inc. |
Oligosaccharides synthétiques pour un vaccin contre neisseria meningitidis
|
WO2011149564A1
(fr)
|
2010-05-28 |
2011-12-01 |
Tetris Online, Inc. |
Infrastructure de jeu informatique asynchrone hybride interactif
|
EP3153578A1
(fr)
|
2010-07-06 |
2017-04-12 |
Novartis Ag |
Compositions immunogènes dérivées de norovirus et procédés
|
GB201015132D0
(en)
|
2010-09-10 |
2010-10-27 |
Univ Bristol |
Vaccine composition
|
GB201101665D0
(en)
|
2011-01-31 |
2011-03-16 |
Novartis Ag |
Immunogenic compositions
|
WO2012085668A2
(fr)
|
2010-12-24 |
2012-06-28 |
Novartis Ag |
Composés
|
CN102068690A
(zh)
*
|
2010-12-31 |
2011-05-25 |
北京民海生物科技有限公司 |
多价肺炎球菌荚膜多糖结合疫苗及其制备方法
|
ES2681698T3
(es)
|
2011-03-02 |
2018-09-14 |
Glaxosmithkline Biologicals Sa |
Vacunas de combinación con menores dosis de antígeno y/o adyuvante
|
WO2012130764A1
(fr)
|
2011-03-29 |
2012-10-04 |
Bayer Materialscience Ag |
Utilisation d'une préparation aqueuse pour revêtement de surfaces en bois destinée à créer une sensation de toucher naturel
|
KR20140019410A
(ko)
|
2011-03-29 |
2014-02-14 |
바이엘 인텔렉쳐 프로퍼티 게엠베하 |
자연스러운 감촉 효과를 달성하기 위해 목재 표면을 코팅하기 위한 수성 제제의 용도
|
GB201106225D0
(en)
|
2011-04-13 |
2011-05-25 |
Glaxosmithkline Biolog Sa |
Fermentation process
|
JP6088507B2
(ja)
|
2011-07-08 |
2017-03-01 |
ノバルティス アーゲー |
チロシンライゲーションの方法
|
WO2013016460A1
(fr)
|
2011-07-25 |
2013-01-31 |
Novartis Ag |
Compositions et procédés d'évaluation de l'immunogénicité fonctionnelle de vaccins contre un parvovirus
|
US9358284B2
(en)
|
2011-09-14 |
2016-06-07 |
Glaxosmithkline Biologicals Sa |
Methods for making saccharide-protein glycoconjugates
|
MX354924B
(es)
|
2011-11-07 |
2018-03-22 |
Novartis Ag |
Molecula portadora que comprende un antigeno spr0096 y un spr2021.
|
GB2495341B
(en)
|
2011-11-11 |
2013-09-18 |
Novartis Ag |
Fermentation methods and their products
|
DE102011118371B4
(de)
|
2011-11-11 |
2014-02-13 |
Novartis Ag |
Zur Impfung von Menschen geeignete Zusammensetzung, die ein Diphtherie-Toxoid umfasst, sowie Verfahren zu deren Herstellung
|
DE102011122891B4
(de)
|
2011-11-11 |
2014-12-24 |
Novartis Ag |
Fermentationsmedium, das frei von tierischen Bestandteilen ist, zur Herstellung von Diphtherie-Toxoiden zur Verwendung bei der Impfung von Menschen
|
EP2592137A1
(fr)
|
2011-11-11 |
2013-05-15 |
Novartis AG |
Support de fermentation sans composants dérivés d'animaux pour la production des toxoïdes diphtériques adaptées à l'utilisation du vaccin humain
|
GB201121301D0
(en)
|
2011-12-12 |
2012-01-25 |
Novartis Ag |
Method
|
EP2822584A1
(fr)
|
2012-03-08 |
2015-01-14 |
Novartis AG |
Vaccins combinés comprenant des agonistes du tlr4
|
SA115360586B1
(ar)
|
2012-03-09 |
2017-04-12 |
فايزر انك |
تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
|
JP2015518845A
(ja)
|
2012-05-22 |
2015-07-06 |
ノバルティス アーゲー |
髄膜炎菌血清群xコンジュゲート
|
KR102057217B1
(ko)
|
2012-06-20 |
2020-01-22 |
에스케이바이오사이언스 주식회사 |
다가 폐렴구균 다당류-단백질 접합체 조성물
|
EP2892553A1
(fr)
|
2012-09-06 |
2015-07-15 |
Novartis AG |
Vaccins combinatoires avec méningococcus de sérogroupe b et d/t/p
|
CN105307684A
(zh)
|
2012-10-02 |
2016-02-03 |
葛兰素史密丝克莱恩生物有限公司 |
非直链糖缀合物
|
ES2848048T3
(es)
|
2012-10-03 |
2021-08-05 |
Glaxosmithkline Biologicals Sa |
Composiciones inmunogénicas
|
SG11201502599TA
(en)
|
2012-10-12 |
2015-05-28 |
Glaxosmithkline Biolog Sa |
Non-cross-linked acellular pertussis antigens for use in combination vaccines
|
KR20140075196A
(ko)
|
2012-12-11 |
2014-06-19 |
에스케이케미칼주식회사 |
다가 폐렴구균 다당류-단백질 접합체 조성물
|
EP2743695A1
(fr)
|
2012-12-12 |
2014-06-18 |
Nanogap Sub NM Powder, S.A. |
Procédés et réactifs pour la détection de biomolécules au moyen de luminescence
|
EP2934574A1
(fr)
|
2012-12-18 |
2015-10-28 |
GlaxoSmithKline Biologicals SA |
Conjugués de protection contre la diphtérie et/ou le tétanos
|
PL3363806T3
(pl)
*
|
2012-12-20 |
2022-12-19 |
Pfizer Inc. |
Sposób glikokoniugacji
|
ITMI20130142A1
(it)
*
|
2013-01-31 |
2014-08-01 |
Biosynth Srl |
Vaccini glicoconiugati comprendenti unita' di base di un costrutto molecolare esprimente epitopi multipli incorporati
|
MY172181A
(en)
|
2013-03-08 |
2019-11-15 |
Janssen Vaccines & Prevention Bv |
Acellular pertussis vaccine
|
AU2014289342B2
(en)
*
|
2013-07-07 |
2018-05-31 |
Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. |
Synthetic vaccines against Streptococcus pneumoniae type 1
|
CN105593238B
(zh)
|
2013-07-11 |
2020-09-08 |
诺华股份有限公司 |
使用微生物转谷氨酰胺酶进行赖氨酸特异性化学酶法蛋白质修饰
|
EP4098276A1
(fr)
|
2013-09-08 |
2022-12-07 |
Pfizer Inc. |
Compositions utilisables contre neisseria meningitidis et procédés associés
|
HRP20231504T1
(hr)
*
|
2014-01-21 |
2024-03-01 |
Pfizer Inc. |
Polisaharidi kapsule iz bakterije streptococcus pneumoniae i njihovi konjugati
|
EP3193918A4
(fr)
|
2014-09-18 |
2018-06-20 |
University of Maryland, Baltimore |
Vaccin conjugué à large spectre permettant de prévenir des infections par klebsiella pneumoniae et pseudomonas aeruginosa
|
US9107906B1
(en)
|
2014-10-28 |
2015-08-18 |
Adma Biologics, Inc. |
Compositions and methods for the treatment of immunodeficiency
|
EP3215226A4
(fr)
|
2014-11-05 |
2018-05-30 |
The United States Of America As Represented By The Secretary Of The Navy |
Constructions antigéniques synthétiques contre campylobacter jejuni
|
US10500261B2
(en)
|
2014-11-05 |
2019-12-10 |
The United States Of America As Represented By The Secretary Of The Navy |
Synthetic antigen constructs against campylobacter jejuni
|
EP3034516A1
(fr)
|
2014-12-19 |
2016-06-22 |
Novartis AG |
Purification de polysaccharides capsulaires de streptocoques
|
GB201518684D0
(en)
|
2015-10-21 |
2015-12-02 |
Glaxosmithkline Biolog Sa |
Vaccine
|
WO2017085586A1
(fr)
*
|
2015-11-20 |
2017-05-26 |
Pfizer Inc. |
Compositions immunogènes destinées à être utilisées dans des vaccins pneumococciques
|
GB201610599D0
(en)
|
2016-06-17 |
2016-08-03 |
Glaxosmithkline Biologicals Sa |
Immunogenic Composition
|
EP3474890A1
(fr)
|
2016-06-22 |
2019-05-01 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften E. V. |
Composition de conjugué polysaccharide pneumococcique-protéine
|
EP3269385A1
(fr)
|
2016-07-12 |
2018-01-17 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Composition de conjugués de polysaccharide-protéine pneumococcique
|
EP3530285B1
(fr)
|
2016-10-20 |
2023-08-09 |
KM Biologics Co., Ltd. |
PROCÉDÉ DE PRODUCTION D'UN VACCIN CONJUGÉ HIB UTILISANT DU PRP
DE POIDS MOLÉCULAIRE REDUIT
|
BE1025162B9
(fr)
|
2016-12-06 |
2019-01-07 |
Glaxosmithkline Biologicals Sa |
Procede de purification pour les polysaccharides capsulaires
|
US11197921B2
(en)
|
2017-01-31 |
2021-12-14 |
Merck Sharp & Dohme Corp. |
Methods for making polysaccharide-protein conjugates
|
CN118021947A
(zh)
|
2017-01-31 |
2024-05-14 |
辉瑞大药厂 |
脑膜炎奈瑟菌组合物及其使用方法
|
US10259865B2
(en)
|
2017-03-15 |
2019-04-16 |
Adma Biologics, Inc. |
Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
|
SG11202006388SA
(en)
|
2018-02-05 |
2020-07-29 |
Sanofi Pasteur Inc |
Multivalent pneumococcal polysaccharide-protein conjugate composition
|
WO2019203599A1
(fr)
*
|
2018-04-18 |
2019-10-24 |
에스케이바이오사이언스 주식회사 |
Polysaccharides capsulaires de streptococcus pneumoniae et conjugués immunogènes de ceux-ci
|
EP3824019A1
(fr)
|
2018-07-19 |
2021-05-26 |
GlaxoSmithKline Biologicals SA |
Procédés de préparation de polysaccharides séchés
|
WO2020043874A1
(fr)
|
2018-08-31 |
2020-03-05 |
Glaxosmithkline Biologicals Sa |
Vaccin conjugué contre haemophilus influenzae utilisant une vésicule de membrane externe de bordetella
|
JP2022513458A
(ja)
|
2018-12-12 |
2022-02-08 |
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム |
O-結合型グリコシル化のための修飾キャリアタンパク質
|
WO2020165711A1
(fr)
|
2019-02-11 |
2020-08-20 |
Pfizer Inc. |
COMPOSITIONS DE NEISSERIA MENINGITIDIS<i /> ET PROCÉDÉS ASSOCIÉES
|
EP3757217A1
(fr)
|
2019-06-27 |
2020-12-30 |
GlaxoSmithKline Biologicals S.A. |
Procédés de purification de protéines
|
EP3777884A1
(fr)
|
2019-08-15 |
2021-02-17 |
GlaxoSmithKline Biologicals S.A. |
Composition immunogène
|
CA3155669A1
(fr)
|
2019-09-27 |
2021-04-01 |
Pfizer Inc. |
Compositions de neisseria meningitidis et methodes associees
|
EP3799884A1
(fr)
|
2019-10-01 |
2021-04-07 |
GlaxoSmithKline Biologicals S.A. |
Compositions immunogènes
|
EP3900739A1
(fr)
|
2020-04-21 |
2021-10-27 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Conjugués saccharides synthétiques de streptococcus pneumoniae à une protéine de membrane conservée
|
EP3919076A1
(fr)
|
2020-06-02 |
2021-12-08 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Vaccins synthétiques d'oligosaccharide contre le streptococcus pneumoniae avec des formulations d'adjuvant de microparticules
|
WO2021250628A1
(fr)
|
2020-06-12 |
2021-12-16 |
Glaxosmithkline Biologicals Sa |
Immunisation bactérienne à l'aide d'un vaccin à nanoparticules
|
US20230226175A1
(en)
|
2020-06-25 |
2023-07-20 |
Glaxosmithkline Biologicals Sa |
Modified exotoxin a proteins
|
EP4243862A1
(fr)
|
2020-11-13 |
2023-09-20 |
GlaxoSmithKline Biologicals SA |
Transporteurs de protéine bactérienne et procédés de conjugaison
|
WO2023111826A1
(fr)
|
2021-12-14 |
2023-06-22 |
Glaxosmithkline Biologicals Sa |
Immunisation bactérienne utilisant des constructions de nanoparticules en épingle à cheveux qbêta
|
WO2023200704A1
(fr)
|
2022-04-11 |
2023-10-19 |
Sanofi Pasteur Inc. |
Conjugaison protéine-saccharide avec du cyanoborohydrure de sodium
|
GB202215414D0
(en)
|
2022-10-18 |
2022-11-30 |
Glaxosmithkline Biologicals Sa |
Vaccine
|